CD274 and gastroesophageal junction adenocarcinoma: In the Phase 2 KEYNOTE-059 study of pembrolizumab in recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, patients with a PD-L1 positive status (combined positive score [CPS] ≥ 1) had a higher ORR compared with patients with a PD-L1 negative status (CPS < 1) (15.5 versus 6.4%, respectively) [7].